Active substance
Results for the substance cangrelor
1 result
About this active substance
Cangrelor is an antiplatelet medication used to prevent blood clot formation in patients undergoing interventional procedures such as coronary angioplasty. It works by reversibly inhibiting P2Y12 receptors on the surface of platelets, thereby preventing platelet aggregation.
Cangrelor is administered intravenously and has a rapid onset of action, making it useful in emergency situations or for patients who cannot take oral antiplatelet medications. Its effects wear off quickly after discontinuation, reducing the risk of prolonged bleeding.
This medication is often used as a bridging therapy for patients requiring temporary discontinuation of other antiplatelet agents before surgery. It may also be used in combination with other anticoagulant medications to provide optimal protection against thrombotic events.
Side effects may include bleeding, allergic reactions, or, in rare cases, a decrease in platelet count. Patients should be closely monitored during treatment to prevent complications.
Cangrelor is administered intravenously and has a rapid onset of action, making it useful in emergency situations or for patients who cannot take oral antiplatelet medications. Its effects wear off quickly after discontinuation, reducing the risk of prolonged bleeding.
This medication is often used as a bridging therapy for patients requiring temporary discontinuation of other antiplatelet agents before surgery. It may also be used in combination with other anticoagulant medications to provide optimal protection against thrombotic events.
Side effects may include bleeding, allergic reactions, or, in rare cases, a decrease in platelet count. Patients should be closely monitored during treatment to prevent complications.